New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of remission and significantly improved depth of remission.[1] With I+V, undetectable minimal residual disease (uMRD) in peripheral blood (PB) was sustained by 85 percent of patients one year after end of treatment.1 The safety and tolerability profile of I+V was consistent with CLL treatment in an older population with comorbidities.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress (Abstract #LB1902). “In the GLOW study, two very active blood cancer treatments are combined to create a complementary therapeutic regimen with the hope that deep responses might enable treatment-free remission for patients,” said Arnon Kater†, M.D., Ph.D., deputy head of hematology, University of Amsterdam Faculty of Medicine, the Netherlands and p...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Acute Leukemia | Allergy & Immunology | Anemia | Arrhythmia | Atrial Fibrillation | Biotechnology | Bleeding | Brain | Cancer | Cancer & Oncology | Cancer Therapy | Cancer Vaccines | Carcinoma | Cardiac Arrhythmia | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Child Development | Children | Chronic Leukemia | Chronic Lymphocytic Leukemia | Chronic Pain | Clinical Trials | Environmental Health | Food and Drug Administration (FDA) | Gastroenterology | Genetics | Headache | Health Management | Heart | Hematology | Hormones | Hypertension | Infectious Diseases | Laboratory Medicine | Learning | Legislation | Leukemia | Lymphoma | Macroglobulinemia | Melanoma | Migraine | Netherlands Health | Neurology | Neuroscience | Neurosurgery | Nonmelanoma Skin Cancer | Oral Cancer | Pain | Pharmaceuticals | Pneomococcal Vaccine | Pneumonia | Politics | Pregnancy | Primary CNS Lymphoma | Pulmonary Hypertension | Science | Skin | Skin Cancer | Skin Graft | Study | Thrombocytopenia | Toxicology | Universities & Medical Training | Vaccines | Veterinary Vaccinations | Waldenstrom's Macroglobulinemia | Women